Home›Trial›NCT06179160
NCT06179160Phase 1RECRUITING

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Study Summary

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

Conditions
Solid Tumors
Interventions / Drugs
INCB161734CetuximabRetifanlimabGEMNabPmFOLFIRINOXFOLFOXFOLFIRIINCA33890
View on ClinicalTrials.gov ↗
Sponsor
INCY
Incyte Corporation
Oncology
F35/100
Study Details
Enrollment710 participants
Primary Completion—
Lead SponsorIncyte Corporation
Data Retrieved2026-04-11 02:55:29.647472+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 710 participants
Sponsor Catalyst Profile

Incyte Corporation (INCY) is the sponsoring company for this trial. BiotechSign currently grades this company F (35/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

INCY Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.